Hester Biosciences Ltd: 75% of World’s Goat Vaccine, 100% of Investors’ Confusion 🐐💉

1. At a Glance

Founded in 1987 by Rajiv Gandhi (no, not that Rajiv Gandhi, calm down), Hester is India’s second-largest poultry vaccine maker and the undisputed king of goat & sheep vaccines. With 75% global market share in PPR vaccines and over 35% in poultry vaccines domestically, the company has a global footprint but Indian margins. Current story: sales growth crawling at 4–5%, but PAT in Q1 FY26 suddenly jumped 159% YoY. Investors scratching heads: “Are we a slow-growth defensive or a high-growth biotech rocket?” The market P/E of 48x says: maybe both, maybe neither.

2. Introduction

Animal healthcare is not exactly cocktail-party glamorous — nobody brags, “Bro, I’m into goat vaccines.” But Hester has quietly built itself into a powerhouse, supplying to 35+ countries, partnering with the Bill & Melinda Gates Foundation, OIE, and GALVmed, and serving farmers, poultry integrators, and livestock owners.

The company is basically an agri–pharma hybrid: when bird flu comes, Hester spikes; when cattle fall sick, Hester milks; when goats sneeze, Hester sneezes cash. Its product mix has also diversified — poultry vaccines (historical breadwinner), livestock vaccines (new driver), and a fledgling pet-care division.

But investors complain: topline growth is stuck in single digits, debt has crept up to ₹213 Cr, and ROE has slipped below 10%. Is this a case of an over-vaccinated stock? Or is the expansion cycle (Nepal, Tanzania, Kadi upgrades) about to finally kick in?

Let me ask you: would you pay SaaS multiples (48x) for a goat vaccine monopoly?

3. Business Model (WTF Do They Even Do?)

Hester runs four verticals:

1. Poultry Healthcare (~48% of FY24 rev, down from 73% in FY22):
   50+ poultry vaccines, diagnostic labs, mastitis programs. Hit badly in FY23 when high feed costs reduced bird placements. Recovery visible, but poultry still volatile.
2. Animal Healthcare (~43%):
   Flagship division now. PPR vaccine monopoly, Goat Pox dominance, plus LSD (Lumpy Skin Disease) vaccines during outbreaks. Government immunisation programs (like PPR eradication by 2030) are big demand drivers.
3. Petcare (~9%):
   Launched FY23. Growing 49% YoY. Pet supplements, gut health, joint care, grooming products. Basically, “Pedigree meets Zandu Balm.”
4. Exports (~14% of revenue):
   Focus on Africa, Nepal, a bit of South America. India still 86%.

Capacity?

• Gujarat (Kadi): 6.25 bn doses
• Nepal: 1.24 bn
• Tanzania: 1.5 bn
• Ongoing expansion: doubling Kadi capacity to 13.45 bn doses, plus a fill–finish line.

4. Financials Overview